North America Fill Finish Manufacturing Market Share and Forecast by 2027

The fill finish manufacturing market in North America is expected to grow from US$ 2,009.28 million in 2020 to US$ 3,887.13 million by 2027; it is estimated to grow at a CAGR of 9.9% from 2020 to 2027.

Biologics constitute a majority of the top-selling drugs, and they presently represent one of the fastest-growing pharmaceutical industry segments. Since the launch of recombinant protein-based therapies, ~30 years back, the overall biologics market has grown at an annual rate of more than 12%. Further, more than 5,000 biopharmaceutical product candidates are currently under development. Although biopharmaceuticals offer significant profit margins, high development costs and complex production protocols are they key concerns of the sponsors of these pharmacological interventions. As a result, several start-ups and pharmaceutical giants have begun outsourcing different processes of their business operations to contract service providers. According to the 2017 Nice Insight CDMO survey, ~54% of 700 respondents claimed their collaborations with contract service providers for clinical and commercial-scale product development projects. Moreover, outsourcing jobs to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) reduce the requirement of capital investments, provide access to larger production capacities, decrease the time-to-market of products, and lower risks associated with commercialization of products. Fill finish is the final step in the production process, and it is one of the most crucial stages of drug manufacturing. Biologics require special procedures and equipment for fill finish operations to ensure product integrity and safety. Thus, the rise in demand for biologics has resulted in an equivalent need for flexible aseptic fill finish technologies. Pharmaceutical drug manufacturers collaborate with contract service providers to leverage their experience and expertise in the latest fill finish technologies. Currently, over 115 companies are actively providing services for the fill finish of biologics. Many service providers have also acquired other players in the recent past to enhance their service offerings. For instance, Sanofi has outsourced the manufacturing of its biologics to Boehringer Ingelheim. Moreover, AbbVie operations have successfully developed and delivered drug products for more than 130 years; over 14 million small-volume parenterals (SVPs) are filled annually across AbbVie’s global network, and the filled products distributed to over 175 countries in the world. Benefiting from a fully integrated Science and Technology group supporting both biologics drug substance (DS) and drug product (DP) development, AbbVie also has a good audit and regulatory track record with proven clinical and commercial success.

The outbreak of the COVID–19 pandemic in late 2019 has disturbed various trades and businesses across the world. The North American countries such as the U.S. and Canada are highly affected, and their economies have fallen down dramatically. However, the pandemic has brought several growth opportunities to the pharmaceutical and biopharmaceutical companies to strengthen their research and development for innovating vaccine against the coronavirus. For instance, In October 2020, CRB, a provider of project delivery solutions for vaccine and critical therapy manufacturers, completed the design and construction of a large-scale facility for Grand River Aseptic Manufacturing (GRAM). GRAM has been selected by the U.S. government to increase domestic pharmaceutical manufacturing for vaccines or therapeutics against COVID-19. In September, GRAM entered into an agreement with Janssen Pharmaceuticals, one of the Companies of Johnson & Johnson, to support the manufacture of its SARS-CoV-2 vaccine candidate, including technical transfer and fill and finish manufacture. GRAM's new 60,000 sq.-ft. The facility in Grand Rapids, MI, was built using CRB's ONEsolution project delivery method and is one of three GRAM manufacturing facilities. The newest facility was designed to increase GRAM's large-scale fill and finish capacity with room to expand as demand grows.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America fill finish manufacturing market. The North America fill finish manufacturing market is expected to grow at a good CAGR during the forecast period.

North America Fill Finish Manufacturing Market Segmentation

North America Fill Finish Manufacturing Market – By Product

• Consumables

• Prefilled Syringes
• Vials
• Cartridges
• Other Consumables

• Instruments

North America Fill Finish Manufacturing Market – By End User

• Contract Manufacturing Organizations
• Biopharmaceutical Companies
• Other End Users

North America Fill Finish Manufacturing Market – By Country

• US
• Canada   
• Mexico       

North America Fill Finish Manufacturing Market – Companies Mentioned

• Becton, Dickinson and Company (BD)                                                                                  
• West Pharmaceutical Services, Inc.                          
• Gerresheimer AG                                                         
• I.M.A. Industria Macchine Automatiche S.P.A.      
• Bausch+Strobel                                                             
• Groninger and Co. GmbH                                           
• Maquinaria Industrial Dara SL                                   
• Nipro PharmaPackaging                                              
• SCHOTT AG   
• SGD Pharma
• Stevanato Group
• Syntegon Technology GmbH   
• Optima Packaging Group Gmbh      

North America Fill Finish Manufacturing Report Scope